Elemental selenium promotes PD-L1 lysosomal degradation to enhance antitumor immunotherapy

Aberrant PD-L1 expression and persistent internalization, driving immune evasion and resistance lead to limited immune checkpoint therapeutic efficacy on hepatocellular carcinoma (HCC). Selenium (Se) deficiency downregulates selenoprotein levels and drives immune cell exhaustion. However, whether Se enhances the therapeutic efficiency of PD-L1/PD-1 checkpoint blockade in HCC remains unclear. Here, we identify a selenoprotein-dependent mechanism that promotes targeted PD-L1 degradation and enhances antitumor immunity. Se reduces PD-L1 abundance in tumors to promote antitumor immunity and synergizes with anti-PD-1 antibodies to suppress tumor growth in a tumor-bearing mice model. Mechanistically, Se inhibits the AKT/SLC7A11/HIF-1α signaling cascade, thereby blocking the inflammatory signaling transduction and suppressing de novo PD-L1 synthesis. Se also induces GPX2 and TrxR1 expression, which directly targets the IgC domain PD-L1 and initiates lysosome-dependent degradation. Genetic knockdown of GPX2 and TrxR1 abrogates Se-mediated PD-L1 downregulation and diminishes its immunostimulatory effects. Consistently, analyses of human normal liver, primary HCC, and metastatic tissues reveal a significant inverse correlation between GPX2/TrxR1 expression and PD-L1 levels, which further suggests the critical roles of GPX2 and TrxR1 in controlling HCC progression. Collectively, these findings uncover a selenoprotein-driven PD-L1 degradation pathway, which may shed light on the application of establishing a new paradigm of selenoprotein-mediated lysosomal degradation for HCC immunotherapy.

Authors

Institutions

Publication Details

Journal
Bioactive Materials
Published
2026-11-20
DOI
https://doi.org/10.1016/j.bioactmat.2026.10.035
Primary Topic
Cancer Immunotherapy and Biomarkers
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Elemental selenium promotes PD-L1 lysosomal degradation to enhance antitumor immunotherapy

Haoqiang Lai, Shuoshan Li, Tianfeng Chen, Huajie Zhang et al.
3 links
Bioactive Materials
Cancer Immunotherapy and Biomarkers
article

Elemental selenium promotes PD-L1 lysosomal degradation to enhance antitumor immunotherapy

Haoqiang Lai, Shuoshan Li, Tianfeng Chen, Huajie Zhang, Haimei Zhang, Chang Liu, Guizhen Li
article en

Abstract

Aberrant PD-L1 expression and persistent internalization, driving immune evasion and resistance lead to limited immune checkpoint therapeutic efficacy on hepatocellular carcinoma (HCC). Selenium (Se) deficiency downregulates selenoprotein levels and drives immune cell exhaustion. However, whether Se enhances the therapeutic efficiency of PD-L1/PD-1 checkpoint blockade in HCC remains unclear. Here, we identify a selenoprotein-dependent mechanism that promotes targeted PD-L1 degradation and enhances antitumor immunity. Se reduces PD-L1 abundance in tumors to promote antitumor immunity and synergizes with anti-PD-1 antibodies to suppress tumor growth in a tumor-bearing mice model. Mechanistically, Se inhibits the AKT/SLC7A11/HIF-1α signaling cascade, thereby blocking the inflammatory signaling transduction and suppressing de novo PD-L1 synthesis. Se also induces GPX2 and TrxR1 expression, which directly targets the IgC domain PD-L1 and initiates lysosome-dependent degradation. Genetic knockdown of GPX2 and TrxR1 abrogates Se-mediated PD-L1 downregulation and diminishes its immunostimulatory effects. Consistently, analyses of human normal liver, primary HCC, and metastatic tissues reveal a significant inverse correlation between GPX2/TrxR1 expression and PD-L1 levels, which further suggests the critical roles of GPX2 and TrxR1 in controlling HCC progression. Collectively, these findings uncover a selenoprotein-driven PD-L1 degradation pathway, which may shed light on the application of establishing a new paradigm of selenoprotein-mediated lysosomal degradation for HCC immunotherapy.

Bioactive MaterialsVol. 70
Jinan University (CN), University of Jinan (CN)
National Natural Science Foundation of China, National Outstanding Youth Science Fund Project of National Natural Science Foundation of China
Good health and well-being
Cancer Immunotherapy and Biomarkers
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon